Cardiovascular outcomes of patients treated for non-Hodgkin lymphoma with first-line doxorubicin-based chemotherapy

Authors :: Alexandra, Zduniak
Emilie, Lévêque
Anne, Perdrix
Pascaline, Etancelin
Anne-Lise, Ménard
Pascal, Lenain
Nathalie, Contentin
Louis-Ferdinand, Pépin
Stéphane, Leprêtre
Emilie, Lemasle
Hélène, Lanic
Aspasia, Stamatoullas-Bastard
Leila, Kammoun-Quique
Hervé, Tilly
Fabrice, Bauer
Fabrice, Jardin
Vincent, Camus
Source :: Leukemia & Lymphoma. 63:3340-3350
Publication Year :: 2022
Publisher :: Informa UK Limited, 2022.
Abstract: We conducted a single-center retrospective study to assess cardiovascular (CV) toxicity and treatment discontinuation for CV toxicity in diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) patients treated with immunochemotherapy (R-CHOP-like). Between 2006 and 2017, 433 patients were included (DLBCL

Tools